A Phase 1/2 interventional study of Hydroxychloroquine, Metformin, Sirolimus and Hydroxychloroquine, Metformin, Sirolimus, Dasatanib in Prostate Cancer Recurrent and Solid Tumor, Adult, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Medical University of South Carolina · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing metformin in Prostatic Neoplasms — 2 open to participants now, 6 under way, 2 of them phase 3. Metformin · Prostatic Neoplasms.
Among the 32 studies testing metformin in Prostatic Neoplasms, this one is the 14th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 1/2, and was the 31st registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 32 studies testing metformin in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
University of Arkansas · Sites in United States
Ages 18–100 · Men only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 43 across the 32 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 32 has an industry lead sponsor. The 10 most frequent:
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
21 studies in Prostatic Neoplasms by Medical University of South Carolina: 3 open now, 4 under way, none of them phase 3. Of 15 finished, 9 (60%) have results posted.
Among the 21 studies in Prostatic Neoplasms by Medical University of South Carolina, this one has the largest planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 1/2, and was the 18th registered.
Medical University of South Carolina’s Prostatic Neoplasms studies by the year they started, since 2004.
2 of the studies testing metformin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05036226Medical University of South CarolinaCOAST Therapy in Advanced Solid Tumors and Prostate Cancer | 2027-05-21 |
| NCT06044025University of ArkansasA Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies testing metformin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Medical University of South Carolina’s 21 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.
This is a Phase I/II safety and efficacy study of COAST therapy in patients with advanced cancer for which no satisfactory therapy options exist. An initial Phase I cohort of 18-30 patients with advanced cancer will receive increasing components of the COAST regimen following a traditional 3+3 escalation design. The starting COAST combination includes hydroxychloroquine, sirolimus and metformin (DL1 - base combination). If this three-drug base combination is cleared for safety, two dose levels will be opened for enrollment exploring the safety of the base in combination with either dasatinib or nelfinavir. Patients will be assigned sequentially to DL2A (base + dasatinib) and DL2B (base + nelfinavir). If nelfinavir is deemed unsafe in combination with the base (DL2B is not cleared for safety, regardless of the safety of DL2A), no further drug combinations will be explored since all remaining combinations include nelfinavir. If both dasatinib and nelfinavir are individually safe in combination with the base (DL2A and DL2B are both cleared for safety), two additional dose levels will be explored, the first combining all five drugs and the second exploring nelfinavir at a higher dose. If dasatinib is not safe but nelfinavir is safe in combination with the base (DL2A but not DL2B cleared for safety), then only one additional dose level will be explored combining the base with a higher dose of nelfinavir. If neither DL2A nor DL2B are cleared for safety, then only the base combination may be considered safe. Once a given dose level is cleared for initial DLT evaluation (e.g., 0 of 3 patients have a DLT or at most 1 of 6 have a DLT), additional patients may be enrolled (i.e., 'backfilled') to that dose level while a higher dose level is being evaluated for safety. Prioritization for backfill will be given to dose levels proximal to the current dose level being explored, and to those dose levels with evidence of anti-tumor activity. Backfill patients who are DLT-evaluable will be included in making decisions on dose escalation. Accrual to a dose-level may be halted and additional patients enrolled to a lower dose level that was previously cleared for safety depending on the total number of DLTs observed among all DLT-evaluable patients at that lower dose level (initial and backfill patients). The maximum tolerated mixture is the highest dose level at which at most 1 of 6 patients experiences a DLT or, for a dose level sample size >6 due to additional backfill patients, the highest dose level at which the observed DLT rate is ≤16.7%. The recommended phase 2 dose (RP2D) will be determined based on the totality of data, including the maximum tolerated mixture, dose adjustments, all safety data including any DLT-equivalent events (safety events that meet the criteria for a DLT regardless of treatment cycle and trial phase), and any response data. The study team may recommend a dose level lower than the maximum tolerated mixture as the RP2D based on their review of the data in aggregate. However, the RP2D will not exceed the dose level corresponding to the maximum tolerated mixture. The phase II efficacy trial will evaluate the anti-tumor activity of the COAST RP2D combination in patients with advanced prostate cancer based on a Simon two stage optimum design. The primary endpoint is the16-week PSA progression-free rate following treatment initiation, where PSA progression is defined per PCWG3. A maximum of 29 patients will be enrolled. In the first stage, 10 patients will be accrued. If none of the first 10 patients are PSA progression-free at 16 weeks, we will halt registration. If one or more patients are PSA progression-free at 16 weeks, an additional 19 patients will be enrolled. If 4 or more out of the 29 patients are PSA progression-free at 16 weeks, the treatment will be declared promising. This study is powered at 80% with a one-sided type I error rate of 5%. Specifically, this study has an 80% chance of declaring promise if the true 16-week PSA progression-free rate is at least 20%. If instead the true 16-week PSA progression-free rate is at most 5%, then the study has a 5% chance of declaring promise and a 60% chance of early termination. Phase I patients treated at the RP2D who meet inclusion and exclusion criteria for phase II will be included in the phase II cohort. Treatment will continue until there is 1) unacceptable toxicity (grade 3 or 4 toxicity that does not resolve to grade 1 or less by 28 days after drug withdrawal), 2) institution of new additional cancer therapy, 3) withdrawal of consent, 4) any condition that, in the opinion of the treating physician, renders continued COAST treatment to not be in the patient's best interest, 5) lack of compliance with study procedures by the patient, or 6) PSA progression by 16 weeks of COAST therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: Hydroxychloroquine, Metformin, Sirolimus
Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Dasatanib
Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
Combination Product: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. ·
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · · DasatinibStudies of DasatinibDasatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. ·
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · · DasatinibStudies of DasatinibDasatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
Maximum Tolerated Dose (MTD) - Phase I
Maximum dose achievable without dose limiting toxicities (DLT's)
Time frame: Minimum of 3 months after start of treatment on each dose level
Measure of proportion of patients with disease control - Phase II
Stable disease by RECIST or PCWG3 criteria after 16 weeks of treatment on study.
Time frame: Minimum of 16 weeks after start of treatment, per patient
Change in Quality of Life (QOL) score
To document the change in QOL (via disease-specific FACT questionnaire, composite score) in patients treated with COAST) after two and four cycles of treatment
Time frame: Minimum of 16 weeks of treatment on study
Started Mar 2022 (actual). Primary completion is estimated for May 2027, 62 months after the start.
Of 114 non-industry phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 85. This study's planned 62 months is close to that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hydroxychloroquine · Metformin · Sirolimus · Nelfinavir · Dasatinib
Medical University of South Carolina →